Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.

What was studied

This review looked at real-world use of brexucabtagene autoleucel. It is a CAR T-cell therapy. It was used in adults with mantle cell lymphoma or B-ALL, a type of leukemia. The cancers had come back or did not respond. The team pooled data on response and safety. Cost, hospital use and quality of life were summed up in words.

What they found

The review found 69 papers on 31 groups of people. Pooled response rates fit the trials ZUMA-2 and ZUMA-3. Mantle cell lymphoma had a median overall survival of 40.3 months. B-ALL had 23.3 months. The commonest events were cytokine release syndrome and nerve-related toxicity. Severe events were rarer in real-world groups than in trials. Cost data were few. No real-world quality-of-life data were found.

What it means for patients

The team says real-world results fit the trials. They say the therapy gave a large and lasting benefit in these cancers. They say gaps remain for quality of life and cost.

Why it is not certain yet

Data on cost and quality of life were limited. Only 1 mantle cell study reported lower costs after treatment. The abstract does not rate the quality of the real-world studies.

Source

Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.